2022_Outcomes_Digi | Page 47

45
HEART FAILURE RESEARCH
Physicians on the medical staff participate in various heart failure trials and publications throughout the year that pave the way for the future of medicine . In fiscal year 2022 , the advanced heart failure team participated in 34 active trials and 42 peer-reviewed publications . Baylor Dallas was also a top ten enroller in seven studies , received five grants and had 43 podium presentations .
Grants awarded
The Variability of Donor-Derived Cell-Free DNA After Heart Transplantation . Principal investigator : Timothy Gong , MD , FACC .
Impact of Virus Infection on Donor-Derived Cell-Free DNA After Heart Transplantation Program . Principal investigator : Amit Alam , MD .
Feasibility of Bicarbonate-Based Purge Fluid in Abiomed Impella ® Device Implantation . Principal investigator : Cesar Guerrero-Miranda , MD , FACC , FHFSA .
Single-transcript sequencing of heart-transplantrelated acute hepatitis C infection : A single-patient extension of TROJAN-C to gather pilot data in support of future NIH grant application . Principal investigator : Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA .
COVID-19 Critical Care Consortium : Cardiac Sub-Study . Principal investigator : Dan Meyer , MD .
New England Journal of Medicine publication
Advanced heart failure and transplant cardiologists on the medical staff at Baylor University Medical Center are contributing on innovative clinical trials for COVID-19 . The following publication , led by Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA , an advanced heart failure cardiologist on the medical staff at Baylor University Medical Center , was featured in the New England Journal of Medicine in January 2022 .
Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients We conducted a randomized , double-blind , placebocontrolled trial involving non-hospitalized patients with COVID-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression ( age ≥60 years , obesity , or certain coexisting medical conditions ). Among non-hospitalized patients who were at high risk for COVID-19 progression , a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87 % lower risk of hospitalization or death than placebo .
Key clinical trials FY22

# 3 Enroller Worldwide

ARRAY-797-301 - A phase 3 , multinational , randomized , placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin a / c gene mutation . Principal investigator : Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA .

# 5 Enroller Worldwide

GUARDIAN REGISTRY - Global utilization and registry database for improved heart preservation ( GUARDIAN ). Principal investigator : Dan Meyer , MD .

# 3 Enroller in the US

HELIOS-A - A phase 3 global , controlled , open-label study to evaluate the efficacy and safety of ALN-TTRSC02 in patients with hereditary transthyretin amyloidosis ( hATTR amyloidosis ). Principal investigator : Parag Kale , MD , FACC , FHFSA .
AIM-HIGHer - Assessment of implantable cardiac contractility modulation ( CCM ) in the heart failure group with higher ejection fraction . Principal investigator : Amarinder Bindra , MD .
rest - Prospective non-randomized post market study collecting clinical data on safety and effectiveness of the remedē ® System . Principal investigator : Parag Kale , MD , FACC , FHFSA .
TRIFECTA - Trifecta-Heart Study : Comparing the ddcfDNA test to MMDx microarray test and central HLA antibody test . Principal investigator : Shelley Hall , MD , FACC , FHFSA , FAST .
For more information and a complete list of updated clinical trials : BRITrials . BSWSites . com .
Baylor Scott & White Heart and Vascular Hospital - Dallas | Advanced Heart Failure